This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chakroborty, D. Articles by Basu, S. Search for Related Content PubMed PubMed Citation Articles by Chakroborty, D. Articles by Basu, S.

Depleted Dopamine in Gastric Cancer Tissues

Dopamine Treatment Retards Growth of Gastric Cancer by Inhibiting Angiogenesis

¹ Signal Transduction and Biogenic Amines Laboratory and ² Department of Medical Oncology, Chittaranjan National Cancer Institute, Calcutta, ³ Mayo Clinic Cancer Center and Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, and ⁴ Department of Pathology, Institute of Postgraduate Medical Education and Research, Calcutta, India

ABSTRACT

Purpose: It has been recently shown that the catecholamine neurotransmitter dopamine (DA) strongly and selectively inhibits vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-induced angiogenesis. Gastric cancer is highly angiogenic and is dependent on VEGF for its growth and progression. Because substantial amounts of DA present in normal stomach tissues has been implicated in several gastric functions, we therefore investigated the role, if any, of this neurotransmitter in the growth and progression of gastric cancer.

Experimental Design: Initially, the status of DA and tyrosine hydroxylase, the rate-limiting enzyme required for DA synthesis, were determined in human gastric cancer tissues and in N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastric cancer tissues of rats. On the basis of our observation of inverse correlation between stomach DA and gastric cancer growth, we determined the effect of pharmacological dose of DA on the angiogenesis and growth of MNNG induced gastric cancer in rats and Hs746T human gastric cancer in nude mice.

Results: DA and tyrosine hydroxylase were absent in both human and rat gastric cancer tissues. On the contrary, a low nontoxic pharmacological dose of DA significantly retarded tumor angiogenesis by inhibiting VEGFR-2 phosphorylation in tumor endothelial cells, which expressed DA D₂ receptors. This action of DA was associated with the growth inhibition of both MNNG-induced rat malignant gastric tumors and xenotransplanted human gastric cancer in nude mice.

Conclusions: Our study demonstrates that there is an inverse correlation between endogenous stomach DA and gastric cancer and indicates that DA already in clinical use for other purposes might have a role as an antiangiogenic agent in the treatment of gastric cancer.

This article has been cited by other articles:

				D. Chakroborty, C. Sarkar, B. Basu, P. S. Dasgupta, and S. Basu Catecholamines Regulate Tumor Angiogenesis Cancer Res., May 1, 2009; 69(9): 3727 - 3730. [Abstract] [Full Text] [PDF]

				C. Sarkar, D. Chakroborty, U. R. Chowdhury, P. S. Dasgupta, and S. Basu Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models Clin. Cancer Res., April 15, 2008; 14(8): 2502 - 2510. [Abstract] [Full Text] [PDF]

				C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simon, and A. Pellicer Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2931 - 2937. [Abstract] [Full Text] [PDF]

				C. Cristina, G. Diaz-Torga, A. Baldi, A. Gongora, M. Rubinstein, M. J. Low, and D. Becu-Villalobos Increased Pituitary Vascular Endothelial Growth Factor-A in Dopaminergic D2 Receptor Knockout Female Mice Endocrinology, July 1, 2005; 146(7): 2952 - 2962. [Abstract] [Full Text] [PDF]